Monitoring of Immune Checkpoint Inhibitors Adverse Drug Reactions Through the WHO Vigilyze and French Pharmaco-vigilance Database (Base Nationale de Pharmacovigilance BNPV)

Trial Profile

Monitoring of Immune Checkpoint Inhibitors Adverse Drug Reactions Through the WHO Vigilyze and French Pharmaco-vigilance Database (Base Nationale de Pharmacovigilance BNPV)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Arthritis; Autoimmune disorders; Cancer; Cardiovascular disorders; Endocrine disorders
  • Focus Adverse reactions
  • Acronyms CHIMeRA
  • Most Recent Events

    • 13 Jul 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2023.
    • 13 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jun 2023.
    • 07 May 2018 Planned End Date changed from 1 May 2018 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top